$ALKS insider trading
Over the last 12 months, Alkermes insiders reported no purchases and 28 sales totaling $10.5M across SEC Form 4 filings. 93% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $10.5M 28 events
- Events · 12m
- 28 Form 4 filings, grouped
- Insiders · 12m
- 7 distinct reporters
- 10b5-1 share
- 93% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Sep 3, 2026 | Gaffin David JosephEVP, CLO, Alkermes, Inc. · O | ▼ Sale | 2,034 | $48.01 | $98K | -0.9% | plan |
| Sep 1, 2026 | Hopkinson Craig C.EVP R&D, Chief Medical Officer · O | ▼ Sale | 9,000 | $46.99 | $423K | -12.1% | plan |
| Aug 17, 2026 | Nichols Christian ToddSVP, Chief Commercial Officer · O | ▼ Sale | 7,576 | $49.23 | $373K | -6.9% | plan · 2 tranches |
| Aug 3, 2026 | snyderman nancy lynn MDD | ▼ Sale | 44,472 | $50.35 | $2.2M | -74.3% | — |
| Aug 3, 2026 | Hopkinson Craig C.EVP R&D, Chief Medical Officer · O | ▼ Sale | 9,000 | $48.58 | $437K | -11.5% | plan |
| Aug 3, 2026 | Gaffin David JosephEVP, CLO, Alkermes, Inc. · O | ▼ Sale | 2,034 | $48.58 | $99K | -0.9% | plan |
| Jul 6, 2026 | Gaffin David JosephEVP, CLO, Alkermes, Inc. · O | ▼ Sale | 2,034 | $54.03 | $110K | -0.9% | plan |
| Jul 1, 2026 | Hopkinson Craig C.EVP R&D, Chief Medical Officer · O | ▼ Sale | 9,000 | $51.51 | $464K | -10.9% | plan · 2 tranches |
| Jun 12, 2026 | Wright Christopher ID | ▼ Sale | 2,000 | $45.1 | $90K | -7.2% | plan |
| Jun 4, 2026 | Gaffin David JosephEVP, CLO, Alkermes, Inc. · O | ▼ Sale | 2,034 | $43.05 | $88K | -0.9% | plan |
| Jun 1, 2026 | Hopkinson Craig C.EVP R&D, Chief Medical Officer · O | ▼ Sale | 9,000 | $41.67 | $375K | -10.4% | plan |
| May 29, 2026 | Parisi Samuel JosephVP, Finance (Interim PAO) · O | ▼ Sale | 16,217 | $42.36 | $687K | -67.8% | — |
| May 4, 2026 | Gaffin David JosephEVP, CLO, Alkermes, Inc. · O | ▼ Sale | 2,034 | $33.2 | $68K | -0.9% | plan |
| May 1, 2026 | Hopkinson Craig C.EVP R&D, Chief Medical Officer · O | ▼ Sale | 9,000 | $33.4 | $301K | -10% | plan |
| Apr 6, 2026 | Gaffin David JosephEVP, CLO, Alkermes, Inc. · O | ▼ Sale | 2,034 | $34.57 | $70K | -0.9% | plan |
| Apr 1, 2026 | Hopkinson Craig C.EVP R&D, Chief Medical Officer · O | ▼ Sale | 9,000 | $35.51 | $320K | -9.5% | plan |
| Mar 3, 2026 | Gaffin David JosephEVP, CLO, Alkermes, Inc. · O | ▼ Sale | 4,068 | $29.52 | $120K | -1.7% | plan · 2 tranches |
| Mar 2, 2026 | Parisi Samuel JosephVP, Finance (Interim PAO) · O | ▼ Sale | 6,890 | $29.29 | $202K | -47.2% | plan |
| Mar 2, 2026 | Nichols Christian ToddSVP, Chief Commercial Officer · O | ▼ Sale | 6,000 | $30 | $180K | -5.2% | plan |
| Mar 2, 2026 | Hopkinson Craig C.EVP R&D, Chief Medical Officer · O | ▼ Sale | 9,000 | $29.72 | $267K | -9.1% | plan |
| Feb 2, 2026 | Hopkinson Craig C.EVP R&D, Chief Medical Officer · O | ▼ Sale | 9,000 | $33.93 | $305K | -13.5% | plan · 2 tranches |
| Feb 2, 2026 | Cooke ShaneD | ▼ Sale | 61,200 | $34.57 | $2.1M | -37.1% | plan · 2 tranches |
| Jan 8, 2026 | Hopkinson Craig C.EVP R&D, Chief Medical Officer · O | ▼ Sale | 5,000 | $30 | $150K | -7.5% | plan |
| Jan 2, 2026 | Hopkinson Craig C.EVP R&D, Chief Medical Officer · O | ▼ Sale | 4,000 | $28 | $112K | -6.1% | plan |
| Dec 3, 2025 | Hopkinson Craig C.EVP R&D, Chief Medical Officer · O | ▼ Sale | 3,748 | $30 | $112K | -5.4% | plan |
| Dec 1, 2025 | Hopkinson Craig C.EVP R&D, Chief Medical Officer · O | ▼ Sale | 4,000 | $29.3 | $117K | -5.7% | plan |
| Nov 3, 2025 | Hopkinson Craig C.EVP R&D, Chief Medical Officer · O | ▼ Sale | 9,000 | $30.38 | $273K | -11.4% | plan |
| Oct 15, 2025 | Hopkinson Craig C.EVP R&D, Chief Medical Officer · O | ▼ Sale | 9,000 | $31.53 | $284K | -10.9% | plan |
Every $ALKS filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Alkermes filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $ALKS feed.